Baciullus clausii CSI08, a soil-based microorganism, has been shown to positively influence microbial populations in such a way that exhibits antioxidant effects on the immune system. More than 20 in vitro studies have been conducted on the strain to confirm both safety and efficacy of MuniSpore, Deerland said in the announcement. A full genome sequencing has confirmed that the strain contains no plasmids, no antibiotic resistance, and no deleterious genes,. MuniSpore is GRAS and Star-K Kosher certified.
As a spore-forming microorganism, Bacillus clausii protects itself from harsh conditions until entering an environment ideal for germination, such as the GI tract. This means that MuniSpore remains viable under a wide temperature range, and doesn’t require refrigeration. It also survives passage through the acidic environment of the GI tract, the company said. For these reasons, the probiotic is ideal for use in supplements, foods, and beverages.
MuniSpore is the company’s second spore-forming probiotic strain product, joining Bacillus subtilis DE111.
“We are pleased to add another probiotic spore to our branded ingredient portfolio,” John Deaton, vice president of science and technology, said.
“The addition of MuniSpore as an option for formulation allows our customers to address the increased consumer demand for science-backed probiotic products for immune support,” Sam Michini, Deerland’s vice president of marketing and strategy, added.
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at firstname.lastname@example.org.